Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 276 participants.

Also called NCT03760965

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 276 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03760965
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03760965. Randomized; double masking; primary purpose treatment. Start 2018-11-27 (actual); primary completion 2020-04-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
sotagliflozin (SAR439954)
Intervention (Drug)
placebo
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03760965
Content hash
46950647dac71e11e273782a0a5127879f8685e10254090e4a8e7f1acfba8dfa